Last updated on June 2017

Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL (Agalsidase Alfa)


Brief description of study

This is an open label switch over study to assess the safety and efficacy of PRX-102. Patients treated with agalsidase alfa for at least 2 years and on a stable dose (>80% labelled dose/kg) for at least 6 months. Patients will be screened and evaluated over 3 months while continuing on agalsidase alfa. Following the screening period, the patient will be enrolled and switched from their agalsidase alfa treatment to receive intravenous (IV) infusions of PRX-102 1 mg/kg every two weeks for 12 months. No more than 25% of treated patients will be female.

Clinical Study Identifier: NCT03018730

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kathleen Nicholls, MD

Royal Melbourne Hospital
Parkville, Australia
  Connect »

Michael L West, MD

Capital Health
Halifax, NS Canada
  Connect »

Ales Linhart, MD

Vseobecna fakultni nemocnice v Praze
Prague, Czechia
  Connect »

Christoph Wanner, MD

Universitaetsklinikum Wuerzburg
Wurzburg, Germany
  Connect »

CEM Hollak, MD

Academisch Medisch Centrum
Amsterdam, Netherlands
  Connect »

Camilla Tøndel, MD

Helse Bergen HF Haukeland Universitetssykehus
Bergen, Norway
  Connect »

Pilar Giraldo, MD

Hospital de Dia Quiron Zaragoza
Zaragoza, Spain
  Connect »

Patrick Deegan, MD

Addenbrooke's Hospital
Cambridge, United Kingdom
  Connect »

Derralynn Hughes, MD

The Royal Free Hospital
London, United Kingdom
  Connect »

Ana Jovanovic, MD

Salford Royal NHS Foundation Trust
Salford, United Kingdom
  Connect »